|Day Low/High||56.10 / 60.35|
|52 Wk Low/High||26.80 / 73.54|
The Baudette, Minn.-based company has 79 products generating about $4 billion in sales and a number of other promising therapies in its pipeline.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ANIP, AXU, BLDP, DVD, EGN, GPIC, IEC, IRS, OVBC, PIH, SAIA, VCO, WILC Downgrades: EFOI, LILAK, PCH, PEGA, PNM, PW, SUI, TOT Initiations: None Read on to get TheStreet Quant Ratings' detailed report:
In recent trading, shares of ANI Pharmaceuticals, Inc. have crossed above the average analyst 12-month target price of $66.00, changing hands for $66.39/share.
Trade-Ideas LLC identified ANI Pharmaceuticals (ANIP) as a strong on high relative volume candidate
Investors eyeing a purchase of ANI Pharmaceuticals, Inc. stock, but cautious about paying the going market price of $59.32/share, might benefit from considering selling puts among the alternative strategies at their disposal.
Here's a technical look at how to trade five stocks poised for breakouts.
Investors considering a purchase of ANI Pharmaceuticals, Inc. stock, but tentative about paying the going market price of $47.54/share, might benefit from considering selling puts among the alternative strategies at their disposal.